Denosumab treatment in women with osteoporosis reduces hip cortical porosity
Roger Zebaze(Austin Health), Ego Seeman(The University of Melbourne), David L. Kendler(University of British Columbia), José Zanchetta(Universidad del Salvador), Arne Høiseth, Michael R. McClung(Bone Health and Osteoporosis Foundation), Andrea Wang(Amgen (United States)), Ali Ghasemzadeh(The University of Melbourne), Cesar Libanati(Amgen (United States))
Cited by 1
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k
Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
|New England Journal of Medicine|1997|694